1-3 of 3
Abhijit Agarwal
Close
Sort by
Journal Articles

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Ulrich Jaeger, Constantine S. Tam, Peter Borchmann, Joseph P. McGuirk, Marianne Johansen, Edmund K. Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Gilles Salles, Stephen J. Schuster, Fiona He, Richard T. Maziarz, Sebastian Mayer, Shinichi Makita, Marie J. Kersten, Monalisa Ghosh, Nina Wagner-Johnston, Koji Kato, Paolo Corradini, Hideki Goto, Silvia Colicino, Abhijit Agarwal, Chiara Lobetti-Bodoni, Michael R. Bishop
Journal: Blood Advances
Blood Adv (2022) 6 (16): 4816–4820.
https://doi.org/10.1182/bloodadvances.2021006193
Published: 2022
Includes: Supplemental data
Journal Articles

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Richard T. Maziarz, Jie Zhang, Hongbo Yang, Xinglei Chai, Chengbo Yuan, Elisabeth Schwarz, Mihael Jakovac, Marcela Martinez-Prieto, Abhijit Agarwal, Evgeny Degtyarev, Constantine Tam, Gilles Salles
Journal: Blood Advances
Blood Adv (2022) 6 (8): 2536–2547.
https://doi.org/10.1182/bloodadvances.2021006280
Published: 2022
Includes: Supplemental data
Journal Articles

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia

Michael R. Verneris, Qiufei Ma, Jie Zhang, Amy Keating, Ranjan Tiwari, Junlong Li, Hongbo Yang, Abhijit Agarwal, Lida Pacaud
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5387–5395.
https://doi.org/10.1182/bloodadvances.2020004045
Published: 2021